• R327G topical gel highly effective against MRSA and P. aeruginosa infected burn wounds
• R327G efficacy outcomes statistically significant and superior to comparator antibiotic Soframycin
• R327G demonstrated statistically significant wound healing and contraction

Recce Pharmaceuticals Ltd has announced statistically significant positive efficacy of its R327G topical gel against Methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa, two clinically significant antibiotic-resistant pathogens, in burn wound rat infection models. The study found that R327G achieved a statistically significant reduction in bacterial load compared to untreated control groups, with bacterial counts reduced substantially by Day 4 and highly significant reductions observed by Day 8. Specifically, the reductions corresponded to approximately a 2-log (99%) and 3-log (99.9%) reduction against MRSA, and approximately a 3-log (99.9%) and 4-log (99.99%) reduction against P. aeruginosa. The antimicrobial performance of R327G consistently exceeded that of Soframycin, a standard comparator antibiotic used in topical wound care. R327G further significantly improved the rate of wound healing, with wounds treated with R327G exhibiting accelerated contraction and statistically significant improvements observed throughout the treatment period. These healing outcomes were consistently superior to both the untreated and Soframycin-treated groups. The study is part of Recce's broader burn wound program supported by a US$2 million grant and a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).

The study results support the ongoing development of R327G as a topical treatment for infected wounds, including burns, under Recce Pharmaceuticals' collaboration with the U.S. Department of Defense.